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Background: Ubiquitination is a highly dynamic and reversible process with a central role in cell homeostasis.
Deregulation of several deubiquitinating enzymes has been linked to tumor development but their specific role in
prostate cancer progression remains unexplored.
Methods: RNAi screening was used to investigate the role of the ovarian tumor proteases (OTU) family of
deubiquitinating enzymes on the proliferation and invasion capacity of prostate cancer cells. RhoA activity was
measured in relation with OTUB1 effects on prostate cancer cell invasion. Tumor xenograft mouse model with
stable OTUB1 knockdown was used to investigate OTUB1 influence in tumor growth.
Results: Our RNAi screening identified OTUB1 as an important regulator of prostate cancer cell invasion through the
modulation of RhoA activation. The effect of OTUB1 on RhoA activation is important for androgen-induced repression
of p53 expression in prostate cancer cells. In localized prostate cancer tumors OTUB1 was found overexpressed as
compared to normal prostatic epithelial cells. Prostate cancer xenografts expressing reduced levels of OTUB1 exhibit
reduced tumor growth and reduced metastatic dissemination in vivo.
Conclusions: OTUB1 mediates prostate cancer cell invasion through RhoA activation and promotes tumorigenesis
in vivo. Our results suggest that drugs targeting the catalytic activity of OTUB1 could potentially be used as therapeutics
for metastatic prostate cancer.
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Prostate cancer (PCa) is one of the leading causes of
cancer related death in the western world [1,2]. Mortality
in PCa is due to our inability to provide efficient therapies
for the management of the metastatic disease associated
with the development of castration-resistant prostate
cancer (CRPC). The mechanisms governing metastatic
progression in PCa are poorly understood, although
recurrent genetic changes leading to PTEN and p53
inactivation and to overexpression of c-myc are often
observed in advanced tumors [3,4]. Despite being resistant
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unless otherwise stated.the expression of functional androgen receptor (AR),
which contributes to the growth of these tumors through
multiple mechanisms [5-10]. The AR can cooperate with
oncogenes to promote tumorigenesis, e.g., we have re-
cently shown that AR activation leads to increased PCa
cell invasion through inhibition of c-myc proteasomal
degradation [11].
Protein ubiquitination is a highly regulated process
that controls multiple physiologically and pathologically
relevant mechanisms involved in tumor development.
The degree of ubiquitination of specific proteins is con-
trolled by the concerted actions of E3 ubiquitin ligases,
de-ubiquitinating enzymes (DUBs) and the proteasome
[12,13]. DUBs specifically cleave the isopeptide bonds of
polyubiquitin moieties. Therefore, DUBs are an importantntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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quitin chains built on specific proteins, in addition to
their function in the recycling of ubiquitinated precursors
[13]. The OTU domain containing DUBs (OTUDs) are
cysteine-dependent proteases with poorly characterized cel-
lular functions. An understanding of OTUDs enzymes role
in carcinogenesis is just starting to emerge. It has been
shown that OTUB1 and OTUB2 can regulate DNA dam-
age response and OTUB1 has been found elevated in colon
carcinomas [14-16]. The A20 OTUD regulates NFκB activ-
ity and plays an important role in lymphomas [17], while
deregulation of OTUD1 has been shown in thyroid carcin-
omas [18]. The cellular OTUDs targets, responsible for
their effects on tumorigenesis are generally unknown.
There is little evidence that high affinity protein-
protein interactions beyond those involving polyubiqui-
tin side chains contribute to the specific recognition of
substrates by OTUDs, making target identification dif-
ficult. On the other hand, it has been shown that differ-
ent OTUDs exhibit certain specificity towards different
types of ubiquitin linkages [19]. For example, OTUB1
preferentially processes polyubiquitin chains linked by
Lys48 while OTUB2 favors Lys63 bonds. TRABID
cleaves Lys29 and Lys33, Cezanne shows more activity
towards Lys11 linkages and Otulin cleaves linear ubiquitin
[19,20]. In addition to its canonical activity as polyubiqui-
tin proteases, some OTUDs (e.g OTUB1) can directly
bind and inhibit E2 ubiquitin conjugating enzymes in-
dependently of their enzymatic activity [15,21].
Here we investigated whether members of the ovarian
tumor proteases (OTU) family of DUBs influence the
proliferation and invasion capacity of PCa cells. We
found that OTUB1 plays a critical role not only in the
AR-dependent but also AR-independent cell invasion of
prostate cancer cells in vitro and in vivo through the
modulation of RhoA activity. Besides, the analysis of
prostate cancer clinical samples shows that OTUB1 is
overexpressed in localized tumor as compared to normal
prostate epithelial cells.
Results
siRNA screening identifies OTUB1 as a novel regulator of
prostate cancer cells invasion
We wanted to investigate the potential roles of OTU-
domain containing proteins with cysteine protease
function (OTUD) in prostate cancer cells tumorigen-
esis. Therefore, we performed a small interfering RNA
(siRNA)-based screening against a panel of OTU family
members -OTUB1, OTUB2, OTUD3, OTUD4, OTUD5,
OTUD7B and OTUD7C and TRABID- to measure their
influence in the proliferation and invasion capacity of
LNCaP-FGC cells. The efficiency of the knockdown was
assessed by measuring the reduction of mRNA levels of
each gene compared to scrambled siRNA transfectedcontrols. After transfecting with the siRNA pools, at
least 70% reduction was observed for all OTUD mRNAs
but for OTUD7C mRNA (40%) (Figure 1A, left panel).
Transient transfection of the aforementioned siRNAs
into LNCaP-FGC cells didn’t result in a significant
alteration of cell proliferation in vitro (Figure 1A, middle
panel). LNCaP-FGC cells show a low capacity to invade
through matrigel in vitro, which can be significantly
stimulated by dihydrotestosterone (DHT) treatment
[11]. Therefore, we tested the effects of the OTUD family
targeting siRNAs in DHT-induced invasion capacity of
LNCaP-FGC cells. We found that of all the siRNAs tested,
only the inhibition of OTUB1 expression was able to
significantly affect cell invasion of LNCaP-FGC cells in
presence of DHT (Figure 1A, right panel).
To confirm this observation, two additional individual
siRNAs targeting OTUB1 were used. As shown in
Figure 1B, siRNAs targeting OTUB1 but not control
siRNA reduced OTUB1 protein expression levels while
inhibiting the invasive capacity of LNCaP-FGC cells upon
DHT stimulation. Moreover, overexpression of the prote-
ase inactive OTUB1-C91S mutant [22] also resulted in
diminished invasiveness (Figure 1C), supporting the
regulatory role of OTUB1 in prostate cancer cell inva-
sion. In order to validate these observations as general
phenomena in prostate cancer cells, we analyzed the
effects of OTUB1 in the androgen-insensitive PCa cell
line, PC3. We confirmed that both OTUB1 knockdown
and overexpression of the catalytically inactive mutant
results in diminished invasive activity while having no
effect on cell proliferation (Figure 1D, E). Similar effects
were observed using 22Rv1 prostate cancer cells (Additional
file 1: Figure S1) supporting the role of OTUB1 in the
regulation of prostate cancer cells invasion.
Elevated OTUB1 protein levels in prostate cancer
We next analyzed OTUB1 expression in prostate cancer
by immunohistochemistry using tissue microarrays (TMAs)
(Figure 2). OTUB1 immunoreactivity (IR) was scored as
weak, intermediate or strong (Figure 2A). Analysis of non-
malignant tissue (n = 59) showed strong staining of basal
epithelial and stromal cells, while the staining of luminal
epithelial cells was mainly weak (44%) or intermediate
(49%) (Figure 2B). On the other hand, 40% of the tumors
(n = 70) exhibited strong OTUB1 IR in luminal cells while
only 7% of the cases showed weak IR (Figure 2B). This
significant increase (Chi-square test, p < 0.0001) in OTUB1
IR in the malignant tissue was independent from the
histological grade, Gleason score (Figure 2B). Further-
more, some prostate cancer samples exhibited strong
nuclear staining. The demonstration that OTUB1 is
overexpressed in PCa suggests a role for OTUB1 in
tumorigenesis and invites additional exploration of its
mechanisms of action.
Figure 1 Functions of the OTU-domain containing proteins in prostate cancer progression. (A) LNCaP-FGC cells transfected with siRNAs
targeting different OTU family members were assayed for: (left panel) the knockdown efficiency of the siRNAs measured by quantitative real-time
PCR -results are shown as percentage expression of each gene relative to siRNA control transfected cells; (middle panel) cell proliferation and
(right panel) matrigel cell invasion. (B) Matrigel invasion assay (upper panel) and western blot analysis of OTUB1 expression (lower panel) in
LNCaP-FGC cells transfected with two different siRNAs targeting OTUB1 or a control siRNA, treated with DHT (10 nM). (C) Same as in (B) using
LNCaP-FGC cells transfected with either an empty vector or expression plasmids for wild type OTUB1 (OTUB1-WT) or the protease inactive C91S
(OTUB1-C91S) variant. (D) Measurements of matrigel invasion and (E) cell proliferation of PC3 cells transfected with either siRNAs targeting OTUB1
or expression vectors bearing OTUB1-WT or the C91S variant, as indicated. In all panels, each column represents the average ± SD of at least four
independent replicates and Student´s t test was used for statistical analysis. In (A), *indicates a significant reduction (p < 0.05) of mRNA levels and
invasive capacity between LNCaP-FGC cells transfected with control siRNA compared with the different OTUs siRNAs. In (B) and (C), *indicates a
statistically significant (p < 0.05) change after DHT treatment in cells transfected with the same siRNA or plasmid. #indicates a significant (p < 0.05)
change between cells transfected with siOTUB1, OTUB1-WT or OTUB1-C91S and control transfected cells upon DHT stimulation. In (D), #indicates a sig-
nificant (p < 0.05) change between cells transfected with siOTUB1, OTUB1-WT or OTUB1-C91S versus control transfected cells.
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Figure 2 OTUB1 expression in prostate cancer. (A) Immunohistochemical analysis of OTUB1 expression in prostate cancer. I, prostate sample
showing a gland with normal architecture (white arrow head) and a tumor area with a Gleason score of 6 (black arrow head). In the normal
gland high OTUB1 expression is observed in basal epithelial cells and in adjacent stromal cells, and increased expression is observed in tumor
epithelial cells compared to normal luminal epithelium. II, negative control staining for A. III, example of a prostate tumor with Gleason score of 8
exhibiting moderate staining of epithelial tumor cells. IV, a tumor with Gleason score of 9 showing strong staining of tumor cells. (B) Distribution
of OTUB1 expression across prostate tissue samples with different Gleason grades are shown as bar graphs while relative numbers are shown as pie
charts. Chi-square p value comparing OTUB1 expression in malignant versus non-malignant prostate tissues and OTUB1 expression across the different
histological Gleason score grades are shown. OTUB1 IR is independent of Gleason score; Chi-square p value across Gleason score grades is 0.7.
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LNCaP-FGC cells
We used a phospho-antibody array to explore possible
mechanisms by which OTUB1 regulates cell invasion in
response to DHT treatment. We analyzed changes in thephosphorylation pattern of 46 signaling proteins in extracts
from LNCaP-FGC cells transfected with OTUB1 or control
siRNA and treated with or without DHT. Because DHT
positively regulates cell invasion in LNCaP-FGC cells [3], we
reasoned that pathways regulated by OTUB1 knockdown
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might be of relevance for the regulation of cell invasion.
As shown in Figure 3A, we found that upon DHT treat-
ment cells transfected with control siRNA showed a
significant induction of MSK phosphorylation (S376/
S360), and a more modest induction of Src (Y419),
RSK1/2 (S221), RSK1/2/3 (S380), p27 (T157) and p70-
S6 Kinase (T421/S424) phosphorylation. On the other
hand, we detected a significant reduction in the phos-
phorylation levels of STAT5b (Y699), STAT6 (Y641),
STAT3 (Y705), PLCγ1 (Y783), p53 (S392), p27 (T198),
GSK3α/β (S21/S9), eNOS (S1177), Chk2 (T172) and AKT1
(Ser473). Interestingly, OTUB1 knockdown in the presence
of DHT opposed the effects of androgens resulting in aFigure 3 Androgens and OTUB1 regulate RhoA activity and p53 prote
in protein phosphorylation in LNCaP-FGC cells transfected with control siRN
shows the effects of DHT on siRNA control transfected cells and in the right p
Measurements were performed in duplicates. Students´ t test was applied
consequence of DHT (left panel) and OTUB1 depletion (right panel). p < 0.05 w
Beta-actin expression by western blot in extracts obtained from LNCaP-FGC ce
and OTUB1-WT, OTUB1-C91S variant or empty vector (lower panel) treated wi
LNCaP-FGC cells stimulated with DHT at different time points as indicated
transfected and treated as indicated.significant induction of p53 (S392), AKT (Ser473) and
eNOS (S1177) phosphorylation level (Figure 3A).
The influence of OTUB1 on androgen signaling was
further confirmed by measuring changes in the total
proteome upon OTUB1 knockdown. LNCaP-FGC cells
were metabolically labeled in 3 isotopic configurations:
“heavy”, “medium” and “light”, using the stable isotope
labeling by amino acids in cell culture (SILAC) method-
ology (Methods section and [23]). “Heavy” cells harbored
proteins containing Arginine 10 (Arg10) and Lysine 8
(Lys8) isotopes; “medium” cells carried Arg6/Lys4 isotopes
and “light” cells had Arg0/Lys0 as the only isotopic variants
of these amino acids. “Heavy” and “medium” cells were
then transfected with siRNAs targeting OTUB1 whilein levels in PCa cells. (A) Phospho-protein array analysis of changes
A or an OTUB1 targeting siRNA, treated or not with DHT. Left panel
anel the effects of different siRNAs on DHT treated cells are compared.
to evaluate the statistical significance of the phosphorylation changes
as considered as significant (*). (B) Analysis of p53, MDM2, OTUB1 and
lls transfected with siRNA targeting OTUB1 or siRNA control (upper panel)
th or without DHT. (C) RhoA activity assay on cell extracts purified from
. (D) RhoA activity assay as in (C) using extracts from LNCaP-FGC cells
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tein extracts of the three cell lines were combined in
1:1:1 ratio and digested with trypsin. Resulting peptides
were analyzed by mass spectrometry. Tryptic peptides
are expected to contain single Arg or Lys. Therefore,
peptides originated from “heavy”, “medium” and “light”
cells will differ in mass accordingly to the isotopic labeling.
Intensity comparison of isotopic peptides will accurately
reflect differences in peptide abundance [24]. Interest-
ingly, we observed an overrepresentation of androgen-
regulated proteins (9/34) among those with reduced
expression after OTUB1 knockdown (e.g. Prostatic acid
phosphatase, ACPP [25]; prostate specific antigen, KLK3;
MALT1; NDRG1 [26]) (Table 1). These results supported
the novel function of OTUB1 as positive mediator of
androgen signaling.
OTUB1 regulates RhoA activity and p53 levels in
LNCaP-FGC cells
In a previous study we described the capacity of OTUB1
to modulate bacterial uptake through the modulation of
RhoA activity [27]. Reduced levels of p53 have been
associated with increased fibroblast cell motility through
the activation of the RhoA small GTPase [28]. Our find-
ings that p53 (S392) phosphorylation levels are reduced
in LNCaP-FGC cells by DHT stimulation and stimulated
by OTUB1 knockdown, suggest that the p53/RhoA path-
ways may also be involved in androgen regulation of cell
invasion. In order to test this hypothesis, we first ana-
lyzed p53 protein levels in LNCaP-FGC cells expressing
OTUB1 siRNAs or an OTUB1 catalytically inactive vari-
ant (OTUB1-C91S). As shown in Figure 3B, p53 protein
levels decreased in DHT stimulated cells, while these
effects are blocked by OTUB1 siRNA or forced overex-
pression of OTUB1-C91S mutant. Interestingly, these
changes in p53 abundance are not accompanied with
alteration in the levels of the p53-E3-ubiquitin ligase
MDM2. It is also important to notice that OTUB1
depletion in the absence of androgen stimulation does
not further increase p53 expression (Figure 3B). These
results indicate that OTUB1 activity modulate androgen
actions on the regulation of p53 expression in PCa cells.
Next, we studied the influence of androgen treatment
on RhoA activity in LNCaP-FGC cells through the quan-
titation of the GTP-bound RhoA fraction (Figure 3C).
The experiments show that DHT treatment increased
the level of active RhoA but not the total RhoA levels,
while no effects were observed for the GTPases Rac and
Cdc42 (data not shown). On the other hand, a signifi-
cant reduction of active but not total RhoA levels was
observed in cells transfected with two different siRNAs
targeting OTUB1 or with the inactive OTUB1-C91S
variant (Figure 3D), supporting a role for OTUB1 in the
regulation of RhoA activation by androgens.RhoA mediates the effects of OTUB1 on cell invasion and
the regulation of p53 levels
Having identified p53 and active RhoA as OTUB1 regu-
lated proteins in LNCaP-FGC cells, we next investigated
the role of these proteins in androgen induced cell inva-
sion. First, we used siRNAs to test the effects of reduced
levels of p53 on the DHT regulation of RhoA activity
and matrigel invasion. As shown in Figure 4A, transfec-
tion with p53 siRNA causes a reduction in expression
levels of p53 comparable to that observed after DHT
treatment in cells transfected with control siRNA (~30%
reduction). Downregulation of p53 either by siRNA or
by DHT treatment does not alter total levels of OTUB1
or RhoA. On the other hand, p53 knockdown leads to a
small increase in the amount of GTP bound RhoA in
the absence of androgen treatment, although the levels
were significantly lower than those observed upon DHT
treatment and insufficient to significantly promote cell
invasion in the absence of DHT stimulation (Figure 4A,
right panel). Treatment with DHT of cells transfected
with p53 targeting siRNA leads to further reduction in
the levels of p53 (50% reduction) and enhanced cell
invasion. The knockdown of p53 did not cause a signifi-
cant increase on RhoA activation by DHT in comparison
with control cells treated with the hormone.
Having failed to observe major effects of p53 downreg-
ulation on RhoA activity levels, we next analyzed
whether RhoA activity influences p53 actions in prostate
cancer cells. We measured p53 levels in cells where
RhoA activity was inhibited either by expression of
shRNA targeting RhoA or through the expression of a
dominant negative form of RhoA (DN-RhoA). As shown
in Figure 4B, reduced expression of RhoA in DHT
treated cells leads to increased p53 protein levels as
compared with DHT treated control cells. This effect is
concomitant to a reduction in cell invasion, confirming
a role of RhoA in the regulation of both p53 levels and
cell invasiveness in prostate cancer cells. Similar results
were obtained when analyzing cells expressing DN-
RhoA (Figure 4C). These cells exhibit elevated p53 pro-
tein levels both in the absence and presence of DHT and
show reduced cell invasiveness upon DHT stimulation,
despite the fact that significant amounts of endogenous
wild type levels of RhoA are expressed in these cells.
Conversely, the overexpression of RhoA constitutive
active form (Q63L-RhoA) resulted in reduced levels
of p53 and enhanced cell invasiveness even in cells
deprived of DHT. From these experiments we can con-
clude that RhoA activation is essential for DHT induc-
tion of cell invasion and also mediates the effects of
DHT on the regulation of p53 protein levels.
Our results also suggest that OTUB1 effects on RhoA
activation are independent of changes in p53 levels. We
tested this hypothesis further by analyzing PC3 prostate
Table 1 Proteins regulated upon OTUB1 knockdown in LNCaP-FGC cells
Gene name Uniprot Log2(siOTUB1_1/siControl) Log2(siOTUB1_2/siControl) Mean (SD)
ACPP P15309 −7.23 −3.08 −5.15 (2.94)
ACTA2 P62736 −3.52 −5.65 −4.58 (1.51)
SHROOM3 Q8TF72 −3.75 −3.24 −3.49 (0.36)
KLK3 P07288 −3.52 −2.72 −3.12 (0.57)
TAGLN Q01995 −2.44 −3.36 −2.9 (0.65)
DES P17661 −3.69 −1.95 −2.82 (1.23)
KPRP Q5T749 −2.33 −2.75 −2.54 (0.3)
ST14 Q9Y5Y6 −1.03 −3.95 −2.49 (2.07)
DCD P81605 −2.60 −2.34 −2.47 (0.19)
CASP14 P31944 −3.23 −1.44 −2.34 (1.27)
STAM Q92783 −1.36 −2.18 −1.77 (0.58)
ACTC1 P68032 −1.05 −2.36 −1.7 (0.93)
ANXA2 P07355 −1.17 −2.17 −1.67 (0.71)
HSPB1 P04792 −1.20 −1.91 −1.56 (0.5)
DTNB O60941 −1.57 −1.55 −1.56 (0.02)
SNX2 O60749 −0.82 −1.84 −1.33 (0.72)
BLMH Q13867 −1.44 −1.09 −1.27 (0.25)
MICAL1 Q8TDZ2 −1.02 −1.43 −1.23 (0.29)
WDR7 Q9Y4E6 −1.17 −1.26 −1.21 (0.06)
MALT1 Q9UDY8 −1.28 −0.99 −1.13 (0.2)
RAB8A P61006 −0.75 −1.23 −0.99 (0.34)
NOC2L Q9Y3T9 −1.04 −0.89 −0.96 (0.1)
ARHGAP35 Q9NRY4 −1.19 −0.73 −0.96 (0.32)
UBE2K P61086 −1.09 −0.81 −0.95 (0.2)
USP39 Q53GS9 −1.19 −0.69 −0.94 (0.36)
HMGCS2 P54868 −0.72 −1.12 −0.92 (0.28)
QSOX1 O00391 −0.92 −0.89 −0.9 (0.02)
TOR1AIP1 Q5JTV8 −0.75 −0.91 −0.83 (0.11)
ADAM9 Q13443 −0.86 −0.73 −0.79 (0.09)
LAMC1 P11047 −0.77 −0.80 −0.79 (0.02)
NUP88 Q99567 −0.71 −0.86 −0.79 (0.1)
YWHAB P31946 −0.68 −0.73 −0.71 (0.03)
NDRG1 Q92597 −0.65 −0.75 −0.7 (0.07)
FAM160B1 Q5W0V3 −0.66 −0.66 −0.66 (0)
DBR1 Q9UK59 0.65 0.59 0.62 (0.05)
SLC4A2 P04920 0.89 0.75 0.82 (0.1)
POLA1 P09884 0.69 1.14 0.91 (0.32)
DDX42 Q86XP3 0.92 1.13 1.02 (0.15)
TTN Q8WZ42 1.50 1.22 1.36 (0.2)
PTGFRN Q9P2B2 2.04 1.66 1.85 (0.27)
Proteins showing changes in expression after OTUB1 knockdown using two different siRNA, compared to control siRNA transfected LNCaP-FGC cells. Androgen
regulated proteins are highlighted. Fold changes are shown as log2 of the ratio between the intensity of the proteins in the siRNA transfected and control siRNA
transfected cells. Mean values and Standard deviation (SD) for both experiments are shown on the right column.
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Figure 4 RhoA activity mediates the effects of OTUB1 on p53 expression and matrigel invasion in PCa cells. (A) Western blot analysis for
the indicated proteins and RhoA activity assay (left panel) of LNCaP-FGC cells transfected with p53 siRNA or control siRNA and treated with or
without DHT. Matrigel invasion assay for the same cells is shown on the right. Quantification of p53 expression relative to beta-Actin levels is
indicated. p53 levels in untreated-control transfected cells were set as 1. Western blot and matrigel invasion assays as in (A) were performed using
cells transfected with RhoA shRNA or control plasmid (B), wild type (WT), constitutively active (Q63L) or dominant negative (DN) alleles of RhoA
(C) and the combination of WT-RhoA and siRNA against OTUB1 (E) in the presence of DHT or control vehicle. (D) RhoA activity assay as in (A) on
PC3 cells transfected with siRNAs targeting OTUB1 or control siRNA. In invasion assays, each column represents the average ± SD of at least four
independence replicates. *indicates statistically significant (p < 0.05) changes after DHT treatment in cells transfected with the same siRNA or
plasmid. #indicates significant (p < 0.05) differences between control transfected cells versus cells tranfected with other siRNAs or plasmids in the
presence of DHT. & indicates significant (p < 0.05) differences between cells transfected with siOTUB1 and cells transfected with siOTUB1 and
WT-RhoA in the presence of DHT. αindicates significant (p < 0.05) differences between cells transfected with Q63L-RhoA and control cells in the
absence of DHT.
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OTUB1 (Figure 1C), but lacks expression of p53 and
AR. We showed that cells transfected with two inde-
pendent OTUB1 targeting siRNAs exhibit significantly
lower GTP bounded RhoA as compared to cells trans-
fected with control siRNA (Figure 4D), confirming that
OTUB1 regulation of RhoA also occurs independently of
p53 or the AR.In the next experiments, we tested whether the
OTUB1 effects on cell invasion are driven through the
regulation of RhoA activity. We analyzed whether over-
expression of RhoA can overcome the inhibitory effects
of OTUB1 siRNA-based knockdown on cell invasion. As
shown in Figure 4E, overexpression of WT-RhoA slightly,
although significantly, induces the invasive capacity of
LNCaP-FGC cells upon DHT stimulation. Importantly,
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observed after OTUB1 knockdown in DHT treated
cells. In parallel, RhoA overexpression counteracts the
effect of OTUB1 knockdown on the levels of p53 and its
downstream target p21. These findings confirm that
RhoA is an important mediator of OTUB1 effects on
cell invasion and p53 expression.
OTUB1 regulates anchorage independent growth in vitro
and tumor development in vivo
In order to test the possible function of OTUB1 in the
regulation of tumor growth in vivo, we generated PC3
cells that stably express a short hairpin (sh) RNA target-
ing OTUB1 expression or a scramble control shRNA.
First, we tested these cells for their anchorage inde-
pendent growth capacity. Inhibition of OTUB1 expres-
sion in PC3 cells significantly reduced the number of
colonies formed in soft agar as compared to control
cells (Figure 5A). These cells were then grafted subcuta-
neously into the nude athymic mice (n = 4) and tumor
size was estimated weekly using a caliper. As shown in
Figure 5B, tumors resulting from cells expressing re-
duced levels of OTUB1 (Figure 5C), exhibited signifi-
cant delay in tumor growth, with tumor sizes of only
27% as compared to controls. Accordingly, tumors bearing
OTUB1 shRNA showed lower levels of the proliferation
marker Ki-67 (Figure 5C). Finally, we assessed the occur-
rence of metastases in mice grafted orthotopically in the
prostate. As shown in Figure 5D and 5E, PC3-shOTUB1
cells exhibited reduced orthotopic tumor growth and
reduced incidence of lymph node metastases. Interest-
ingly, PC3-shOTUB1 grafted mice only exhibited lymph
node metastatic foci while PC3-shControl grafted mice
also showed metastatic foci in liver and kidney.
Discussion
In this study we have demonstrated that OTUB1 protein
levels are elevated in prostate cancer and contribute to
the induction of cell invasion through a mechanism that
involves the activation of RhoA. The analysis of xeno-
graft models also demonstrates that OTUB1 can modu-
late tumor growth and metastatic development in vivo.
OTUB1 belongs to the OTU domain containing family
of cysteine-dependent proteases (OTUDs). OTUB1 is
able to cleave the isopeptide bond within polyubiquitin
chains, with a preference for Lys48 linked ubiquitins
[22], while other members of the family have specificity
for other types of ubiquitin linkages [22,29-31]. Given
that most of the studies exploring OTUDs activity utilize
short poly-ubiquitin polymers unattached to target pro-
teins, it is unclear whether they reflect the functions of
these proteins in vivo. Indeed, recent studies have shown
that OTUB1 can negatively regulate Ubc13 mediated
Lys63 linked ubiquitination of RNF168 in a manner thatis independent of its protease activity and dependent on
a direct interaction through the N-terminal domain of
the protein [15,32]. Similar results were obtained in
U2OS cells where overexpression of both WT and the
OTUB1-C91S inactive mutant led to an increased ex-
pression of p53 through interference with UBCH5/
MDM2 mediated ubiquitination [33]. Therefore, through
its interactions with E2 ubiquitin ligases, OTUB1 can
modulate biological processes independently of its pro-
teolytic activity. This is particularly interesting when
considering our observations that in prostate cancer
cells, OTUB1 mediates the androgen inhibition of p53
through a mechanism that requires an intact OTUB1 cata-
lytic motif and seems to be independent from MDM2
concentration changes (Figure 3B). Moreover, in LNCaP-
FGC cells cultured in the absence of androgens, OTUB1
depletion is unable to alter p53 levels (Figures 3B and 4E).
In contrast, OTUB1 is required for androgen signaling
leading to the inhibition of p53 expression. Overall, our
findings suggest that OTUB1 regulation of p53 in prostate
cancer cells is indirect and the result of altered androgen
signaling. Therefore, the mechanisms whereby OTUB1
regulate p53 seem to change in tissue and stimuli specific
manner.
We found that in prostate cancer cells, OTUB1 has
the capacity to modulate cell invasion of both AR+ and
AR- cells in a manner that seems to be dependent on
the presence of an intact active site. While overexpres-
sion of WT OTUB1 leads to increased cell invasion, the
expression of the OTUB1-C91S variant mimics the
effects of OTUB1 siRNA knockdown, leading to reduced
cell invasion (Figure 1). Similar effects were observed
when RhoA activity was measured, suggesting that in
addition to the non-canonical effects of OTUB1 previ-
ously described, its proteolytic activity is important for
some of its biological actions, in line with what have
been shown for the regulation of ER alpha levels by this
protein [34].
In previous studies we have shown that androgens can
regulate cell invasion [3,11]. Here we demonstrate that
the ability of androgens to induce the activation of RhoA
is modulated by OTUB1 and leads to an increased cell
invasion capacity as well as downregulation of p53
(Figure 3B). The antagonistic relationship between p53
status and Rho activity is well known, as it has been
demonstrated that either loss of p53 or expression of
p53 mutants promotes the activation of RhoA and the
induction of cell invasion [28]. These findings seem to
place RhoA downstream of p53 actions. On the other
hand, there is also evidence for alternative mechanisms
where signaling molecules involved in the regulation of
cell motility can influence p53 function. For example,
it has recently been shown that JMY which function as
an actin nucleation factor in the cytosol to promote cell
Figure 5 (See legend on next page.)
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Figure 5 PC3 cells xenografts expressing shOTUB1 show decreased tumorigenesis and metastatic activity. (A) PC3 cells expressing a
short harpin cDNA targeting OTUB1 or a scramble control were used to measure anchorage independent growth in soft agar. (B) PC3-shOTUB1
or PC3-shControl cells were implanted subcutaneously (n = 4 mice per group) and tumor growth was measured weekly. (C) Immunohistochemical
analysis of the expression of OTUB1 and Ki-67 in the xenograft tumors. Three random areas per mouse and tumor were counted for the expression
of both proteins and the results are shown as percentage of positive cells. (D) PC3-shOTUB1 or PC3-shControl cells were implanted into the prostate
of nude mice (n = 4). After 8 weeks, orthotopic tumors were surgically removed and their volumes analyzed. (E) Number of lymph node meta-
static foci per mouse. *indicates statistically significant (p < 0.05) changes between shOTUB1 cells and shControl cells.
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co-activator of p53. The enhanced translocation of JMY
into the nucleus upon DNA damage negatively regulates
motility while enhancing p53 function [35,36]. In
androgen receptor expressing LNCaP-FGC prostate
cancer cells, androgens´ negative regulation of p53 levels
also relies on the regulation of cell motility pathways
depending of RhoA activation. While siRNA mediated
downregulation of p53 in androgen depleted cells cause
minor effects on RhoA activation, the knockdown of
RhoA is sufficient to enhance p53 expression in andro-
gen treated cells.
We have previously reported the ability of OTUB1 to
proteolytically remove ubiquitin moieties from (pre-
sumably Lys48-linked) polyubiquitinated RhoA in vitro,
suggesting that OTUB1 actions on RhoA activity may
be the consequence of direct actions leading to reduced
proteasomal degradation and stabilization of RhoA [27].
This interpretation is now challenged by our findings
that OTUB1 downregulation has little effects on RhoA
cellular content, while proteasome inhibition leads to
reduced rather than increased activation of RhoA in
response to androgen treatment (Additional file 2:
Figure S2). This finding suggests that the proteasome
may be involved in the inactivation of RhoA inhibitors
in LNCaP-FGC cells, which may be directly or indir-
ectly targeted by OTUB1. Given the myriad of regu-
latory proteins controlling RhoA activity, it is difficult
to perform a comprehensive analysis of the effects of
OTUB1 in these pathways. In this context it is relevant
to mention that a recent study have demonstrated that
androgens activate RhoA in muscle cells by promoting its
membrane translocation subsequent to the polyamination
of RhoA. Therefore, the modulation of polyamine metabo-
lisms by OTUB1 needs to be considered among the pos-
sible mechanisms explaining its effects on RhoA [37]. A
number of protein-protein interaction screenings has
only identified a handful of OTUB1 interacting proteins,
with not known function as RhoA regulators, question-
ing the assumption that OTUB1 has domains for the
specific recognition of enzymatically targeted proteins
in addition to those that bind Lys48 linked polyubiquitin
[22]. Our own attempts to investigate an interaction be-
tween RhoA and OTUB1 in LNCaP-FGC cells by multiple
means have failed to demonstrate a direct association.Therefore, additional studies are needed to identify the
mechanisms used by OTUB1 to regulate RhoA function.
The biological functions of OTUB1 are poorly under-
stood, in part because of the lack of sufficient insight
into which proteins or biological processes are modu-
lated by this DUB. Here, we provide the first demonstra-
tion that OTUB1 protein levels are altered in human
prostate cancer (Figure 2) and that downregulation of
OTUB1 expression limits tumorigenesis in vivo (Figure 5).
Our findings on the role of OTUB1 in the regulation of
RhoA and p53 activity suggest that these are relevant
pathways to explain the effects of OTUB1 in tumor
growth. Ample amount of evidences has linked prostate
cancer progression to loss of p53 function [38]. Moreover,
a significant overlap exists between the genomic changes
associated with different stages of prostate cancer progres-
sion with those induced by oncogenic RhoA mediated
transformation (Additional file 3: Figure S3), suggesting
that this is an important pathway for prostate tumor pro-
gression in humans. Interestingly, we also demonstrated
that downregulation of OTUB1 levels leads to effects on
AKT1 and eNOS phosphorylation that antagonize those
induced by DHT. Future studies should address whether
these changes are relevant for OTUB1 effects on tumori-
genesis and the mechanisms whereby OTUB1 regulates
these proteins.
Conclusions
In summary, we demonstrate that OTUB1-mediated ac-
tivation of RhoA promotes cell invasion of prostate can-
cer cells. OTUB1 also promotes tumorigenesis in vivo
in good agreement with the overexpression observed in
prostate cancer tumors. Thus, our results would sup-
port the investigation of drugs targeting the catalytic
activity of OTUB1 as potential therapy for advance
prostate cancer.
Methods
Cell lines, materials and plasmids
LNCaP-FGC and PC-3 PCa cell lines were purchased
from ATCC (Rockville, MD) in 2010 and cultured as
described previously [3]. Dihydrotestosterone (DHT) was
obtained from Amersham (Braunschweig, Germany). Bor-
tezomib and MG132 were obtained from LC Laboratories
(Woburn, MA, USA). Sea plaque agarose for soft agar
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ME, USA). The plasmids bearing the HA-tagged OTUB1
allele and the C91S mutant have been described previously
[27]. The functional screening was performed using siRNA
pools purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). For RhoA Knockdown shRNA pools
from Santa Cruz Biotechnology (Santa Cruz, CA, USA)
were used. OTUB1 individual siRNAs were purchased
from Qiagen (Hilden, Germany) Transfections were
performed using the Neon transfection system (Invitro-
gen, Carlsbad, CA, USA) according to the manufactur-
er's instructions. Stable PC3 cell lines were generated
by transfecting the SureSilencing shRNA plasmid for
human OTUB1 (Qiagen, Hilden, Germany) encoding the
Neomycin resistant gene and the pGL4.17-[luc2/puro]
(Promega, Madison, WI, USA), PC3-shOTUB1, or the
same plasmid containing a scramble sequence which does
not match any human gene, PC3-shControl. Expression
vectors for WT-RhoA, Q63L-RhoA and DN-RhoA were
described previously [39].
RNA extraction, cDNA synthesis and real-time–PCR
These procedures were carried out as earlier described
[3]. All measurements were performed in triplicate for
each sample and normalized to the internal control
gene, β-actin. Four independent experiments were per-
formed. The primers are listed in Additional file 4:
Table S1.
Western blotting
The western blotting procedure was carried out as de-
scribed earlier [10]. Mouse anti-human OTUB1 antibody
was obtained from Cell Signaling (Fremont, CA, USA).
Mouse monoclonal rose against p53 (D0-7) and p21 (F-5),
rabbit polyclonal anti-RhoA (119) and human β-actin
(sc-130301) antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA) and mouse monoclonal
anti-RhoA (ARH03-A) was from Cytoskeleton (Denver,
CO, USA).
Phospho-antibody arrays
Profiling of phosphorylation changes of 46 different signal-
ing proteins in response to DHT treatment or OTUB1,
siRNA mediated knockdown was performed using the
Proteome Profiler antibody array (ARY003) from R&D
systems (Minneapolis, MA, USA), using the manufac-
turer’s instructions. Signal intensities were quantified by
densitometry using ImageJ software [40].
Cell proliferation assay
LNCaP-FGC cells were placed in phenol red-free RPMI
1640 containing 5% DCC-FBS and cultured for 24 h
before stimulation with 10 nM DHT or a vehicle control.
PC3 cells were cultured in RPMI 1640 containing 10%fetal bovine serum. Proliferation was measured using the
xCelligence system (Roche Diagnostics, Indianapolis, IN,
USA), following manufacturer’s recommendations. Cells
were continuously monitored during 96 h and doubling
times calculated based on the impedance values at time
24 h and 96 h. At least three independent experiments
were performed.
Matrigel invasion assay
This procedure was carried out as previously described
[3]. Four independent experiments were performed. In
each set of experiments every group was measured in
triplicate.
Growth in soft agar
This assay was carried out as previously described [11].
Each plate was seeded with 105 cells. Every 3 days, 0.5 ml
of fresh media was added to the cells. After 14 days, the
top layer of the culture was stained with 0.2% iodonitrote-
trazolium chloride, and colonies larger than 0.1mm in
diameter were counted.
Small GTPase activity assay
RhoA activity was analyzed using the Rho Activation
Assay Biochem Kit from Cytoskeleton (Denver, CO,
USA) following manufacturer instructions. The assay is
based on the measurement of GTP-bound RhoA isolated
using Rhotekin bound beads. Likewise, Rac and Cdc42
activity was measured using commercially available kits
(G-LISA Cdc42 and Rac Activation assay Biochem Kit,
Cytoskeleton).
Immunohistochemistry
Tissue micro arrays (TMAs) including formalin-fixed,
paraffin-embedded samples from men diagnosed with
prostate cancer between 1975 and 1995 after trans-
urethral resection of the prostate were analyzed, and
have been previously described in detail [41]. TMAs for
analysis were selected to represent tumors of different
grades; Gleason score (GS) 5 (n = 4), GS 6 (n = 17), GS
7 (n = 18), GS 8 (n = 12), GS 9 (n = 15), and GS 10 (n = 4).
TMA sections, 4 μm thick, were used for IHC essentially
as reported [41], with OTUB1 (1:75, Cell Signaling) as
primary antibody. The epithelial cell staining was scored
as weak, moderate, or strong in each TMA core, and the
general (median) score for non-malignant and malig-
nant cores was reported per patient. The predominant
cellular localization of the staining was recorded. The
research ethic committee in Umeå, Sweden, approved
this study.
Quantitative proteomic profile
LNCaP-FGC cells were metabolically labeled following
the stable isotope labeling by amino acids in cell culture
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for at least 10 generations in RPMI medium (Biowest)
supplemented with 10% dialyzed FBS (Sigma) and 28
and 48 mg/L of stable isotopic variants of arginine and
lysine respectively (Cambridge isotope laboratories,
Inc) as only source for these amino acids. Cells cul-
tured with Arg10 (13C6;
15N4) and Lys8 (
13C6;
15N2)
were denominated “heavy”, “medium” when the amino
acids were Arg6 (13C6;) and Lys4 (4,4,5,5-D4) and
“light” with Arg0 and Lys0. All amino acids were pur-
chased from Cambridge isotope laboratories, Inc.
“Light” cells were transfected with siRNA control while
“heavy” and “medium” cells were transfected with dif-
ferent siRNA targeting OTUB1. Whole cell extracts
were purified and mixed in a 1:1:1 ratio and resolved
by SDS-PAGE. After trypsin in-gel digestion, peptides
were analyzed by LC-MS/MS using an orbytrap mass
spectrometer. The obtained mass spectrometric raw
data were analyzed in the MaxQuant environment [42]
with the integrated Andromeda searching engine and
false discovery rate cut-off for peptide identification of
0.1 [43]. The effects of OTUB1 depletion were calcu-
lated as the result of dividing the normalized intensity of
each “heavy” (siOTUB1_1) and “medium” (siOTUB1_2)
protein by the intensity of the correspondent “light”
(siControl) protein.
Mice xenograft models
Prostate Cancer PC3-shOTUB1 and PC3-shControl
cells were grafted in athymic nude mice either subcuta-
neously or orthotopically into the anterior prostate as
described [44]. In brief, the abdomens of 8-week-
old anesthesized athymic nude mice were surgically
opened under sterile conditions. PC3-shOTUB1 and
PC3-shControl cells (5 × 106) suspended in 50μl of
Matrigel were injected into one lobe of anterior pros-
tate by 25-gauge needle and the abdomens were closed
by silk sutures (4 mice per group). In another set
of mice (PC3-shControl, n = 4; PC3-shOTUB1, n = 5)
cells were implanted with matrigel subcutaneously.
Growth of tumors was monitored weekly using a cali-
per and tumor volume was calculated as described
[45]. Mice harboring tumors in the prostate were killed
8 weeks later and the size of orthotopic prostate
tumors was measured. The number of metastatic foci
was counted. Tissues were fixed and embedded in par-
affin for further analyses. Immunohistochemical detec-
tion of OTUB1 and Ki-67 was performed as described
[46] using antibodies from Cell signaling (OTUB1,
1:75) and Abgent (Ki-67, 1:100). All the experiments
were conducted in compliance with the policies and
regulations of Tianjin Medical University Institutional
Animal Care and Use Committee (Tianjin, China). Ethical
permit SYXK (Tianjin) 2009-0001.Additional files
Additional file 1: Figure S1. OTUB1 depletion inhibits 22Rv1 cells
invasion. Measurements of matrigel invasion of 22Rv1 cells transfected with
either siRNAs targeting OTUB1 or control siRNA. # indicates a significant
(p<0.05) change between cells transfected with siOTUB1 versus control
transfected cells.
Additional file 2: Figure S2. Chemical inhibition of the 26S proteasome
results in reduced amount of active RhoA. LNCaP cells were starved in 5%
charcoal-striped serum for 24h and then treated with 10 nM DHT for 8h
with or without proteasome inhibitors bortezomib or MG132 at the
indicated concentrations. GTP-bound RhoA was pulldown from whole
cell extracts using Rhotekin-RBD beads. Western blot analysis of pulldowns
and whole cell extracts was performed to determine the expression of the
indicated proteins.
Additional file 3: Figure S3. Significant overlap between genes
regulated in prostate cancer and genes regulated by RhoA. (A) Gene
Set Enrichment Analysis (GSEA, Broad Institute, Cambridge, MA, USA) of
the genes with elevated (left panel) or reduced (right panel) expression
levels in localize prostate tumors versus benign prostate tissue [47]
were compared with genes with increased or decreased expression
due to the overexpression of a constitutively active form of RhoA (RhoA-
Q63L) [48]. (B) Genes with elevated (left panel) or reduced (right panel)
expression levels in prostate cancer-derived metastasis [47] versus
localize prostate tumors were compare as in (A) with the same set of
RhoA modulated genes. False Discovery Rate “q” value is shown.
Additional file 4: Table S1. Primers used in this study for RT-PCR.
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